- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BETTER THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,349 | +2,98 % | Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected | PETAH TIKVA (dpa-AFX) - This week's biotech landscape witnessed key FDA meetings being scheduled, IND clearances, complete response letters, sale of oncology assets and clinical trial data readouts... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| IBIO | 2,220 | -9,02 % | Jones Trading initiates iBio stock with buy rating on obesity platform | ||
| TRAWS PHARMA | 1,710 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,698 | +2,19 % | Clear Street raises Ocular Therapeutix price target on wAMD data | ||
| UNITY BIOTECHNOLOGY | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,050 | 0,00 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook | Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential... ► Artikel lesen | |
| ERASCA | 15,120 | 0,00 % | Erasca, Inc. (ERAS): A Bull Case Theory | ||
| DYNE THERAPEUTICS | 15,230 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,545 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| QIAGEN | 39,695 | -2,89 % | Shortseller-Positionen aktuell: freenet, Gerresheimer, Hypoport, Qiagen, Renk, Suss MicroTec, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 86,15 | -4,39 % | Kymera auf TD Cowen Konferenz: Strategische Einblicke in Medikamenten-Pipeline und Partnerschaften | ||
| ARCELLX | 114,26 | 0,00 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 27,410 | 0,00 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| UPSTREAM BIO | 7,800 | 0,00 % | Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | - Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p in new analysis with adjustment for concomitant rescue therapy use - - Secondary endpoints also provided strong... ► Artikel lesen |
BETTER THERAPEUTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BETTER THERAPEUTICS INC finden Sie auf Wallstreet Online.